PADI4 and HLA-DRB1 Are Genetic Risks for Radiographic Progression in RA Patients, Independent of ACPA Status: Results from the IORRA Cohort Study

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Suzuki, Taku ^a,b   Ikari, Katsunori ^a   Yano, Koichiro ^a   Inoue, Eisuke ^a   Toyama, Yoshiaki ^b   Taniguchi, Atsuo ^a   Yamanaka, Hisashi ^a   Momohara, Shigeki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DRB1 ANTIGEN; RHEUMATOID FACTOR;

ADULT; AGE; ALLELE; ANXA3 GENE; ARID5B GENE; ARTICLE; B3GNT2 GENE; CCR6 GENE; CD83 GENE; COHORT ANALYSIS; CSF2 GENE; DISEASE COURSE; DISEASE DURATION; FEMALE; GENDER; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; JAPANESE; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NFKBIE GENE; ONSET AGE; PDE2A ARAP1 GENE; PEPTIDYL ARGININE DEIMINASE TYPE IV GENE; PLD4 GENE; PTPN2 GENE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING; TNFAIP3 GENE;

ANTIBODIES; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HLA-DRB1 CHAINS; HUMANS; HYDROLASES; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84875985769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061045     Document Type: Article

References (51)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637.
2. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964-975.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. (2012) 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64: 625-639.
4. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, et al. (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67: 212-217.
5. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63: 1090-1095.
6. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, et al. (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of by IgA-RF at disease onset. Ann Rheum Dis 65: 453-458.
7. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T, (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64: 196-201.
8. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, et al. (2006) The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 45: 734-740.
9. Wolfe F, (2000) The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 27: 630-637.
10. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, et al. (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 31: 519-525.
11. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, et al. (2004) The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 50: 2082-2093.
12. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, et al. (2009) Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 60: 1242-1249.
13. Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, et al. (2001) Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 28: 1809-1816.
14. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, et al. (1991) Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 18: 1285-1289.
15. Pease CT, Bhakta BB, Devlin J, Emery P, (1999) Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology (Oxford) 38: 228-234.
16. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, et al. (2012) Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 44: 511-516.
17. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, et al. (2011) Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 7: e1002004.
18. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508-514.
19. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, et al. (2006) The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis 65: 905-909.
20. Wagner U, Kaltenhauser S, Pierer M, Seidel W, Troltzsch M, et al. (2003) Prospective analysis of the impact of HLA-DR and-DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatology (Oxford) 42: 553-562.
21. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, et al. (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50: 400-412.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
23. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, et al. (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17: 283-289.
24. Yamanaka H, Tohma S, (2006) Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 16: 75-76.
25. van der Heijde DM, (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27: 261-263.
26. Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, et al. (2010) Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. Ann Rheum Dis 69: 368-373.
27. Keystone EC (2009) Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis. J Rheumatol Suppl 82: 11-16.
28. Shidara K, Inoue E, Tanaka E, Hoshi D, Seto Y, et al. (2011) Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. Rheumatol Int 31: 617-622.
29. Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y, (2006) Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 8: R76.
30. Landewe R, van der Heijde D, (2005) Radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 23: S63-68.
31. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, et al. (2008) Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58: 1293-1298.
32. Keene ON, (1995) The log transformation is special. Stat Med 14: 811-819.
33. McDonald JH (2009) Handbook of Biological Statistics. Baltimore: Sparky House Publishing. 160-164 p.
34. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, et al. (2008) Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis 67: 1153-1158.
35. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, et al. (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39: 360-367.
36. Nakajima A, Inoue E, Shidara K, Hoshi D, Sato E, et al. (2011) Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Mod Rheumatol 21: 594-597.
37. van der Heijde DM, (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2): 74-78.
38. Tsukahara S, Shinozaki M, Ikari K, Mochizuki T, Inoue E, et al. (2008) Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology (Oxford) 47: 41-44.
39. Kobayashi S, Ikari K, Kaneko H, Kochi Y, Yamamoto K, et al. (2008) Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Japanese population. Arthritis Rheum 58: 1940-1946.
40. Rojas-Villarraga A, Diaz FJ, Calvo-Paramo E, Salazar JC, Iglesias-Gamarra A, et al. (2009) Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun 32: 64-69.
41. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, et al. (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34: 395-402.
42. Kang CP, Lee HS, Ju H, Cho H, Kang C, et al. (2006) A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum 54: 90-96.
43. Iwamoto T, Ikari K, Nakamura T, Kuwahara M, Toyama Y, et al. (2006) Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 45: 804-807.
44. Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, et al. (2004) A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 50: 1117-1121.
45. Burr ML, Naseem H, Hinks A, Eyre S, Gibbons LJ, et al. (2010) PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. Ann Rheum Dis 69: 666-670.
46. Martinez A, Valdivia A, Pascual-Salcedo D, Lamas JR, Fernandez-Arquero M, et al. (2005) PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology (Oxford) 44: 1263-1266.
47. Too CL, Murad S, Dhaliwal JS, Larsson PT, Jiang X, et al. (2012) Polymorphisms in peptidylarginine deiminase (PADI) associate with rheumatoid arthritis in diverse Asian populations: evidence from MyEIRA study and meta-analysis. Arthritis Res Ther 14: R250.
48. Hoppe B, Haupl T, Egerer K, Gruber R, Kiesewetter H, et al. (2009) Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 68: 898-903.
49. Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, et al. (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58: 1958-1967.
50. Cha S, Choi CB, Han TU, Kang CP, Kang C, et al. (2007) Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum 56: 1454-1463.
51. Bang SY, Han TU, Choi CB, Sung YK, Bae SC, et al. (2010) Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study. Arthritis Res Ther 12: R115.